Heart failure outcomes in patients with type 2 diabetes mellitus: findings from the cardiovascular outcome trials of antidiabetes agents
Type 2 diabetes mellitus (T2DM) is a recognised risk factor for several cardiovascular (CV) conditions including heart failure (HF). Findings that reflect CV risk associated with T2DM medications have led to regulatory requirement of conducting CV outcome trials (CVOTs) for new antidiabetes drugs. O...
Saved in:
| Main Author: | Stefan D. Anker |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Endocrinology Research Centre
2019-12-01
|
| Series: | Сахарный диабет |
| Subjects: | |
| Online Access: | https://www.dia-endojournals.ru/jour/article/view/10374 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Perioperative Considerations of Novel Antidiabetic Agents in Heart Failure Patients Undergoing Cardiac Surgery
by: Ashley Wang, et al.
Published: (2025-03-01) -
Heart failure in diabetes: From an increased risk to a treatment target
by: Eberhard Standl
Published: (2018-11-01) -
Novel antidiabetic therapies in patients with peripheral artery disease: current perspective
by: Miodrag Janić, et al.
Published: (2024-11-01) -
Glucagon like peptide-1 modulates urinary sodium excretion in diabetic kidney disease via ENaC activation
by: Goh Kodama, et al.
Published: (2025-04-01) -
Modern antihyperglycemic agents prescribed in Russia for type 2 diabetes mellitus
by: Yury Ivanovich Suntsov
Published: (2012-03-01)